Summary SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide) is an anti-tumour agent that has a highly selective toxicity to hypoxic cells. In this study we 
SR 4233 is presently in phase I clinical trials as a potential anti-tumour agent. This drug has a highly selective toxicity to a variety of hypoxic mammalian cell lines in vitro (Zeman et al., 1986) and causes extensive tumour cell death in vivo when combined with radiation Brown & Lemmon, 1990 ), or with agents that induce tumour hypoxia (Brown, 1987; Sun & Brown, 1989) . Previous studies in our laboratory have proposed a metabolic pathway of SR 4233 under hypoxia showing that two major reduction products are found, a two-electron reduction product SR 4317 and a four-electron reduction product SR 4330 (Baker et al., 1988) . However since neither of these is toxic to either hypoxic or aerobic cells, we have suggested that the toxic species is probably the single electron reduction intermediate, necessarily a free radical (Baker et al., 1988; Laderoute et al., 1988; Zeman et al., 1986) . Recent EPR studies have unequivocally identified the production of a free radical from the enzymatic reduction of SR 4233 under hypoxia (Lloyd et al., 1991) . This free radical intermediate is either back-oxidised by molecular oxygen, in the presence of oxygen, to yield superoxide and the parent drug or acquires a second electron, in the absence of oxygen, to form the stable mono-N-oxide, SR 4317. These divergent fates presumably confer the selectivity of the hypoxic metabolism, and the abstraction of the second electron from macromolecules, such as DNA, has been suggested as the cause of the lethal damage to the cells (Costa et al., 1989) .
Several reductases may catalyse N-oxide reduction including the microsomal enzymes NADPH:cytochrome P-450 reductase and cytochrome P-450, as well as the cytosolic enzymes xanthine oxidase, aldehyde oxidase and DT diaphorase (Hewick, 1982; McLane et al., 1983) . Studies by Walton and Workman (1990) have shown that the major reductase for SR 4233 reduction under hypoxic conditions in mouse liver microsomes is cytochrome P-450. However, these investigations do not necessarily mean that the same reductases will be the improtant ones in tumours. Recently, Riley and Workman (1992) have found that SR 4233 may also be a substrate for tumour DT-diaphorase. Since a major determinant of tumour cell toxicity by SR 4233 is its rate of bioreduction under hypoxia (Biedermann et al., 1991) 
Chemicals
SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide) and its reduction products, SR 4317 (3-amino-1 ,2,4-benzotriazine-l-N-oxide) and SR 4330 (3-amino-1,2,4-benzotriazine), were synthesized at SRI International, Menlo Park, CA, by Dr M. Tracy under contract from the National Cancer Institute (contract N01-CM-4761 1). Purified cytochrome P-450 reductase (P-450 reductase) from rat liver microsomes was provided by Dr Wold as described previously (Wolf & Oesch, 1983 (Hirst et al., 1982) . HT KCl, pH 7.5), and resuspended at S x 107 cell ml' in the same buffer. Cell suspension was sonicated by four 10-second bursts with a Sonifer Cell Disruptor (Model W185, Heat System Ultrasonics, INC), at 50% of maximum intensity. The cell suspension tubes were immersed in ice-water during sonication.
Protein assay
Protein concentration was determined by BCA (Pierce Chemical Co., IL) method (Redinbaugh & Turley, 1986) with bovine serum albumin as the standard.
Enzyme assays
The functional state of cytochrome P-450 in tumour cells was detected by measuring a cytochrome P-450-dependent monoxoygenase ethoxycourmarin 0-deethylase activity utilizing the fluorometric determination of the 0-deethylation of 7-ethoxycourmarin (Graeve et al., 1980; Rosenberg et al., 1990) . The reaction mixture, in a total volume of 2 ml, contained MgCl2 (5 mM), BSA (1 mg ml-'), NADPH (0.5 mM), NADH (0.5 mM) 80 mM of potassium phosphate buffer (pH 7.4) and cell sonicates (2 to 10 mg ml-'). After a 5-min preincubation at 37°C, the reaction was initiated by addition of 20 ftl of 7-ethoxycoumarin (0.431iM final) in methanol. The mixture was incubated at 37°C for 20 min with shaking, and the reaction was stopped by the addition of 250 ,sl of ice-cold 15% (w/v) trichloroacetic acid (TCA). For the sample blanks, TCA was added prior to incubation. Following extraction of incubates with 4 ml of chloroform, 2 ml of the organic phase was extracted with 3 ml of 0.01 N NaOH, 1 M NaCl solution. The concentration of 7-hydroxycoumarin in the alkaline phase was determined fluorometrically by a Perkin Elmer LS3 fluorescence spectrophotometer (excitation at 368 nm and emission at 456 nm).
DT diaphorase activity was assayed as the method described by Ernster (Ernster, 1967) . 2,6-dichlorophenolindophenol (DCPIP) was used as the electron acceptor while NADPH was the electron donor.
NADPH-cytochrome P-450 reductase activity was measured as the rate of cytochrome c reduction as described by Omura and Takesue (Omura & Takesue, 1970) . SR 4233 reduction assay All hypoxic incubations were performed in a double sidearmed glass flask (Wheaton Jacketed Reaction Vessels) at 37°C with continuous stirring. The reaction mixture was pregassed for 30 min by humidified 95% N2 and 5% C02, and the gas flow continued throughout the experiment. The enzymes were added 10 min before the initiation of the reaction. The reaction was initiated by the addition of SR 4233 at the appropriate concentrations.
Each reaction mixture contained an enzyme source (0.1 to 1.0 mg ml-' cell sonicates or purified P-450 reductase, or purified xanthine oxidase), enzyme cofactors (0.9 mM NADPH, 0.9 mM NADH, 1 mM hypoxanthine and 2.5 mM N-methylnicotinamide for cell sonicates; NADPH for purified P-450 reductase; hypoxanthine for xanthine oxidase), SR 4233 (60 jM to 200 ltM) and bicarbonate buffered salts solution (BBS) buffer (129 mM NaCl, 26 mM NaHCO3, 5 mM KCl, 3.4 mM KH2PO4, 1.3 mM CaC12, 0.5 mM MgCl2, 0.4 mM MgSO4 and 5 mM glucose, pH 7.4) in a final volume of 10 ml.
Immediately after SR 4233 addition and at each time point, 1 ml of the mixture was removed and added to an equal volume of ice-cold 50% methanol and 2% acetate, centrifuged at 12,000g for 10 min, and the supernatant was taken for fluorescence measurement.
The fluorescence was monitored in a Perkin Elmer LS3 (Hewick, 1992; Rajagopalan, 1980; Walton & Workman, 1990; Wolpert et al., 1973 0.6% and 41.3 ± 2.6% respectively while carbon monoxide (cO) produced a 68.6 ± 5.7% and 58.1 ± 3.7% (mean + s.e., n = 3) inhibition in SCCVII and HT 1080 sonicates respectively.
Different enzyme levels in SCCVII and HT 1080 cells 1 Three NADPH enzyme activities in SCCVII and HT 1080 cells were determined by their standard assays. Table I shows Ithe rates of SR 4233 reduction, cytochrome P-450 levels (expressed as 7-ethoxycoumarin 0-deethylase activity), P-450 reductase activities (reduction of cytochrome c) and DT diaphorase activities (reduction of DCPIP) in SCCVII and HT 20 25 1080 cells. In SCCVII cells, the rate of SR 4317 formation was about 1.7 fold higher than that in HT 1080 cells. The b levels of the enzyme tested were all higher in SCCVII cells than that in HT 1080 cells by the fact of 3.5 (cytochrome P-450), 1.9 (P-450 reductae) and 2.2 (DT diaphorase).
1?/ SR 4233 reduction by purified P-450 reductase Figure 4 shows the rate of SR 4233 reduction by various amount of purified P-450 reductase (0.5 units ml-to 2.0 units ml-'). The unit of this purified enzyme is defined in Materials and methods. 1982; McLane et al., 1983) . In the present study we have all cofactors; (0) shown that SR 4233 is reductively metabolised under hypoxic Eonly; (*) 1 mM conditions to SR 4317 by the rodent and human tumour cell Inicotinamide only.
lines, SCCVII and HT 1080. In both cell lines the reduction experiments.
of SR 4233 was largely dependent upon NADPH (50% and 80% for SCCVII and HT 1080, respectively), a cofactor of a cytochrome P-450, NADPH-P-450 reductase, DT diaphorase and other enzymes. In the presence of NADPH, the reduction was inhibited more than 60% by a specific inhibitor of cytochrome P-450, carbon monoxide, in both cell lines. This suggests that cytochrome P-450 may play an important role 1.0 'in the reduction of SR 4233 in both tumour cell lines. About 30% and 66% of the reduction was dependent upon NADH in SCCVII and HT 1080 cells, respectively. The inhibition studies showed that this in part could be due to the action of DT diaphorase. The other two reductase cofactors, hypoxanthine and N-methylnicotinamide, did not significantly contribute to SR 4233 reduction in either cell lines. Therefore, we conclude that cytochrome P-450 may play the major role in (Walton et al., 1989; Walton & Workman, 1990 ) that cytochrome P-450 is the major reductase in the reduction of SR 4233 based on the 60% to 80% inhibition of reduction by the P-450 inhibitor, carbon monoxide. On the other hand, however, Cahill and White (1990) and Lloyd et al. (1991) found no inhibition of reduction of SR 4233 by carbon monoxide using rat liver microsomes. Whether this disagreement reflects a difference between mouse and human on the one hand, and rat on the other, or a technical problem with the gassing time of carbon monoxide is not clear at present.
SCCVII and HT 1080 cells demonstrated similar KM but differing Vma. This is consistent with their different sensitivities to killing by SR 4233 under hypoxia: SCCVII cells are more sensitive than HT 1080 cells (Biedermann et al., 1991) . In fact, because of the close relationship between rates of drug reduction by different cell types and the sensitivies of these cells to killing by SR 4233 under hypoxia, the present data suggest that an independent measurement of the levels of the appropriate enzyme in a tumour might form the basis of an assay to predict the sensitivity of the tumour to be killed by SR 4233. Our data of such enzyme levels in SCCVII and HT 1080 cells correlated well with the rate of SR 4233 metabolism in these cell lines (Table I) . SR 4233 can be a substrate for a broad spectrum of reductases in vitro. For example, Laderoute et al. (1988) showed that xanthine oxidase could reduce SR 4233 and produce plasmid DNA breakage in vitro. Our data with tumour cells, however, indicate that xanthine oxidase plays a little or no role in the reduction of SR 4233 by either of the cell lines investigated.
A further complication is that the cellular reduction of SR 4233 that is responsible for cell killing may result from a relatively narrow spectrum of enzymes at crucial cellular locations, such as the nuclear membrane. We have shown, for example, that cell killing by SR 4233 under hypoxia is the result of chromosome aberrations apparently produced by enzyme activation very close to the chromosome (Wang et al., 1992) . Drug reduction in these regions may or may not be produced by the same spectrum of enzymes responsible for total cellular reduction.
Approximately 30-40% of SR 4233 metabolism, however, is mediated by as yet unidentified enzymes. Although P-450 reductase could, in principle, catalyse the reduction of SR 4233 directly or via reduction of cytochrome P-450 and account for the remaining activity, without a specific inhibitor, it is difficult to decide what role P-450 reductase does play.
In conclusion, we have shown that SR 4233 is reductively metabolised to SR 4317 by the tumour cell lines, SCCVII and HT 1080, under hypoxic conditions. Cytochrome P-450 may play a major (greater than 60%) role in both cell lines. Also, in agreement with Riley and Workman (1992) , DT diaphorase is the second most important enzyme in reducing SR 4233, particularly in HT 1080 cells. Xanthine oxidase and aldehyde oxidase play little or no role in drug reduction in both cell lines.
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